UAE Pharmaceutical Distribution Reform: What the End of Single-Agent Arrangements Means for the Industry

UAE reforms pharma distribution rules, ending single-agent models from 2026 to strengthen medicine supply resilience and market access.

UAE Pharmaceutical Distribution Reform: What the End of Single-Agent Arrangements Means for the Industry

The UAE is reshaping how pharmaceutical products reach the market. Effective from February 2026, the Emirates Drug Establishment has introduced a requirement for pharmaceutical companies to appoint more than one authorized local agent per product — ending the single-agent distribution model that has long defined market access in the country.

Why the Reform Was Needed

The existing model concentrated supply chain risk with individual distributors. Any disruption — inventory shortages, cold-chain failures, financial disputes, or compliance issues — affecting a sole agent could affect medicine availability across the entire UAE market. The new mechanism, implemented under Federal Decree-Law No. 38 of 2024, is designed to eliminate that vulnerability and ensure supply continuity, particularly for essential and specialised medicines.

Market Context: A Sector Projected to Reach US$8 Billion

The UAE pharmaceutical market generated an estimated US$5 billion in revenue in 2025 and is projected to reach US$8 billion by 2033, growing at around 6% annually. Biologics, biosimilars, and oncology treatments are among the fastest-growing segments — all requiring reliable cold-chain logistics and uninterrupted distribution.

Commercial Implications for Manufacturers and Distributors

For international pharmaceutical companies, the reform requires a review of existing agency agreements, particularly any exclusivity provisions. A multi-agent model can improve supply resilience and channel specialisation, but requires clearer governance on stock allocation, pricing consistency, and partner responsibilities.

For UAE-based distributors, the reform creates both pressure and opportunity. Those with strong logistics infrastructure, digital inventory systems, and hospital tendering expertise are well-placed to expand their portfolio of authorised products.

The reform signals that distribution resilience is now a regulatory priority in the UAE — and a key component of the country’s ambition to become a leading regional life sciences hub.

For more trusted business news, market insights, and investment updates from the UAE and beyond, visit www.moneypetrol.com and stay ahead of the curve.

Watch & subscribe to MoneyPetrol podcasts on YouTube for in-depth conversations with industry leaders and decision-makers.

Follow us on Instagram for real-time updates, expert perspectives, and exclusive content.

Scroll to Top

Get our free newsletter delivered daily to your inbox—subscribe now!